118702-11-7

Name	LY 156735
CAS	118702-11-7
Molecular Formula	C14H17ClN2O2
MDL Number	MFCD00952153
Molecular Weight	280.75
MOL File	118702-11-7.mol

Synonyms

TIK-301 LY 156735

show less show more

Chemical Properties

Boiling point	525.9±50.0 °C(Predicted)
density	1.237±0.06 g/cm3(Predicted)
pka	15.88±0.30(Predicted)

Hazard Information

Uses

TIK-301 (PD-6735) is a chlorinated melatonin derivative and a potent, high-affinity and orally active melatonin MT1 and MT2 receptors agonist with Kis of 0.081 nM and 0.042 nM, respectively. TIK-301 is also a 5-HT2B/5-HT2C receptors antagonist with antidepressant action. TIK-301 has the potential for sleep disorders and other circadian rhythm disorders treatment[1][2][3].

in vivo

In male rats, TIK-301(at doses of 0.8 and 4.0 mg/kg/day) can reduce body weight, and without altering food intake^[1]^[2].
The T_max and half-life of TIK-301 is 1.1 hour and 1 hour, respectively^[1].

IC 50

melatonin MT₁: 0.081 nM (Ki); melatonin MT₂: 0.042 nM (Ki); 5-HT_2C Receptor; 5-HT_2B Receptor

References

[1] Paulis L, et al. Cardiovascular effects of melatonin receptor agonists. Expert Opin Investig Drugs. 2012 Nov;21(11):1661-78. DOI:10.1517/13543784.2012.714771
[2] Rivara S, et al. Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. Curr Top Med Chem. 2008;8(11):954-68. DOI:10.2174/156802608784936719
[3] Carocci A, et al. Melatonergic drugs in development. Clin Pharmacol. 2014 Sep 18;6:127-37. DOI:10.2147/CPAA.S36600

Supplier

cjbscvictory

Telephone13348960310 13348960310

Websitehttps://www.weikeqi-biotech.com/

Beijing Jin Ming Biotechnology Co., Ltd.

Telephone010-60605840 15801484223;

Websitehttp://www.jm-bio.com/

Changzhou Bojia Biomedical Technology Co., Ltd.

Telephone 2122619822

Websitehttps://www.chemicalbook.com/ShowSupplierProductsList849747/0.htm

TargetMol Chemicals Inc.

Telephone 15002134094

Websitehttps://www.targetmol.cn/

PROMPT×

PROMPT
The What'sApp is temporarily not supported in mainland China

Cancel

Determine

Send Inquriy